AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02113813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: oral
Study NCT01827540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT04656028 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: DNA is extracted using the QIAamp® DNA Blood Mini Kit (Qiagen, Germany). The DNA concentration is measured on a Qubit 4.0 fluorometer (Thermo Fisher Scientific, USA (TFS)). NGS is performed on Nextseq 550 (Illumina, San Diego, CA, USA). The library preparation is performed using the SeqCap EZ Prime Choice Library kit (Roche, Basel, Switzerland). The Roche panel is used, consisting of 244 (CDS + 25 bp padding) genes including LDLR, APOB, and PCSK9. Reads are aligned to the reference genome (GRCh37). Sequencing analysis resultes in fastq files. Data processing is performed with BWA, Picard, bcftools, GATK3 and generally followed the GATK best practices for variant calling. For clinical interpretation, genetic variants with frequencies in the gnomAD database \<0.5% are selected. The pathogenicity of variants is assessed according to the ACMG / AMP2015 guidelines. The identified SNPs are validated by Sanger sequencing (3500 DNA Analyzer, TFS).
Study NCT02820610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
Study NCT04656028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Counseling
Description: Motivational counseling will be carried out during Visit 2 and in one month after Visit 2 by certified psychologist with taking into account the results of the psychodiagnostic survey conducted at the first and second visits.~The goals of motivational counseling:~1. Increasing motivation for a healthy lifestyle;~2. Increasing adherence to treatment;~3. Increased motivation to invite relatives for cascade screening. Motivational counseling will be carried out using methods of motivational interviewing, transtheoretical model of changes, cognitive-behavioral therapy, extended preventive counseling.
Study NCT04656028 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lipid analysis
Description: Assessment of total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, alanine aminotransferase.
Study NCT04656028 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lipid analysis
Description: Assessment of total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, alanine aminotransferase.
Study NCT04656028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)
Description: All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage. If somebody has an intolerance to atorvastatin, the drug will be replaced with rosuvastatin and vice versa. In case of intolerance to all drugs from the statin group, the patient will be prescribed ezetimibe with a PCSK9 inhibitor (alirocumab / evolocumab). After receiving the results of the lipid spectrum, ALT, if necessary, the lipid-lowering therapy may be corrected.
Study NCT04656028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)
Description: All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage. If somebody has an intolerance to atorvastatin, the drug will be replaced with rosuvastatin and vice versa. In case of intolerance to all drugs from the statin group, the patient will be prescribed ezetimibe with a PCSK9 inhibitor (alirocumab / evolocumab). After receiving the results of the lipid spectrum, ALT, if necessary, the lipid-lowering therapy may be corrected.
Study NCT04656028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visit 1
Description: Visit 1: initially (on enrollment) - informed consents signing; lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. After this visit patients are randomized to groups with or without genetic testing and then randomized to groups with or without motivational counseling.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform, a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days.
Study NCT04656028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visit 1
Description: Visit 1: initially (on enrollment) - informed consents signing; lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. After this visit patients are randomized to groups with or without genetic testing and then randomized to groups with or without motivational counseling.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform, a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days.
Study NCT04656028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visit 2
Description: Visit 2 (in 2-3 months): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid lowering-therapy and lifestyle; filling all questionnaires. Patients from the group with genetic testing will get the result of this genetic testing. Patients from the group with motivational counseling will get two consultations with a psychologist (motivational counseling on lifestyle modification) during Visit 2 and in one month after Visit 2.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days
Study NCT04656028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visit 2
Description: Visit 2 (in 2-3 months): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid lowering-therapy and lifestyle; filling all questionnaires. Patients from the group with genetic testing will get the result of this genetic testing. Patients from the group with motivational counseling will get two consultations with a psychologist (motivational counseling on lifestyle modification) during Visit 2 and in one month after Visit 2.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days
Study NCT04656028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visit 3
Description: Visit 3 (in 3 months after Visit 2): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days.
Study NCT04656028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visit 3
Description: Visit 3 (in 3 months after Visit 2): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days.
Study NCT04656028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visit 4
Description: Visit 4 (in 12 months after Visit 3): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days.
Study NCT04656028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visit 4
Description: Visit 4 (in 12 months after Visit 3): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days.
Study NCT05186077 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired
Study NCT05186077 — intervention group
Intervention type: OTHER
Intervention: Psychiatric testing
Description: Subjects will be evaluated using psychiatric assessments
Study NCT05186077 — intervention group
Intervention type: OTHER
Intervention: Eye-Tracking
Description: Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.
Study NCT05186077 — intervention group
Intervention type: OTHER
Intervention: Neuropsychology Evaluation
Description: The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function
Study NCT01861275 — intervention group
Intervention type: DEVICE
Intervention: Nasal CPAP
Description: Nasal CPAP treatment for obstructive sleep apnoea
Study NCT03233971 — intervention group
Intervention type: OTHER
Intervention: rPATD Questionnaire
Description: A 5-point Likert scale questionnaire consisting of 22 questions for older adults, and 19 questions of caregivers.
Study NCT00300118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalazine
Description: 4.5 g
Study NCT02184884 — intervention group
Intervention type: DEVICE
Intervention: MACE after OPCAB
Study NCT02184884 — intervention group
Intervention type: DEVICE
Intervention: without MACE after OPCAB
Study NCT02366585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin gel applied to two periodontal pockets
Study NCT02025348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IntelliCap
Description: Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.
Study NCT01164163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib phosphate
Study NCT01164163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01164163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT04889781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: Compare the effect of dexamethasone injection on reducing post-op pain after impacted third molar Surgery
Study NCT04889781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: Compare the effect of Piezosurgery device use on reducing post-op pain after impacted third molar Surgery
Study NCT02820610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: 2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
Study NCT02820610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9 %
Description: 2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
Study NCT04545112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CABG
Description: Elective, on-pump coronary artery bypass (CABG) surgery. Each study subject will receive an internal mammary artery (IMA) conduit to the left anterior descending (LAD) coronary artery, one saphenous vein graft and one XABG medical device.
Study NCT01969175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-glycemic-load and milk-free diet
Study NCT01379443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CTN model of care for children and their families
Description: Parental reports on the quality of life of their children and service needs
Study NCT03252639 — intervention group
Intervention type: PROCEDURE
Intervention: EVT for RAS & PBV acquisition protocol for target kidneys
Study NCT02662686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transfer according to morphological criteria
Description: Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).
Study NCT02662686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer according to the MitoScore results
Description: Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).
Study NCT04624893 — intervention group
Intervention type: DRUG
Intervention: Polatuzumab Vedotin-Piiq
Description: Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
Study NCT01432314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.~C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).~D. Dose:~i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT.
Study NCT01432314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization
Description: A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.~C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop.
Study NCT00235729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
Study NCT00235729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an exact match of lofexidine, less the active ingredient.
Study NCT02695485 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: innervated sensate flap
Description: sensory reconstruction via digital nerve repair with the donor nerve of the flap
Study NCT02158858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610)
Study NCT02158858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT02983981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topicort Topical Spray
Description: open label Topicort spray
Study NCT02897193 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICE dental implant 4.2 mm
Description: ICE dental implant 4.2 mm diameter
Study NCT02897193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICE dental implant 3.2 mm
Description: NICE dental implant 4.2 mm diameter
Study NCT02897193 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Bio's Graft Bovine bone
Description: Alpha Bio's Graft Bovine Bone
Study NCT03734744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D is a fat-soluble vitamin that plays an important role in immune modulation in addition to its classical roles in regulation of calcium homeostasis and bone health
Study NCT02517970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology distraction
Description: Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
Study NCT04163822 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention, only observation
Study NCT04991428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.
Study NCT04991428 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.
Study NCT00123968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA016-00-VP
Description: 1x10\^11 per unit vaccine administered intramuscularly via Bioinjector
Study NCT00123968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: 4 mg administered intramuscularly via injection
Study NCT00123968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-DILUENT013-DIL-VP
Description: Administered intramuscularly via Bioinjector
Study NCT00123968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP placebo
Description: 4 mg administered intramuscularly via injection
Study NCT01056328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SJM Irrigated Cardiac Ablation System
Description: Irrigated ablation catheter
Study NCT01056328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved Open Irrigated RF Ablation System
Description: Irrigated ablation catheter
Study NCT01670149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Tablets
Study NCT01670149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study NCT01907789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ovarian Cancer Screening
Description: Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
Study NCT01907789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic Salpingectomy with Delayed Oophorectomy
Description: Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
Study NCT01907789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Risk-Reducing Salpingo-Oophorectomy
Description: Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
Study NCT01907789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery.